An Open-Label, Dose-Escalation Phase I Clinical Study of T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

NCT07474168 Phase 1 ACTIVE_NOT_RECRUITING

An open label, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301VT in subjects with advanced solid tumor.

Details

Lead sponsor	Zhejiang University
Phase	Phase 1
Status	ACTIVE_NOT_RECRUITING
Enrolment	9
Start date	2025-12-15
Completion	2032-02

Conditions

• Tumor

Interventions

• NW-301VT

Primary outcomes

• Dose-limiting toxicity (DLT) — 28 days following NW-301VT infusion
  Safety

Countries

China